Why Halozyme Therapeutics Inc. Shares Shot Higher

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Halozyme Therapeutics (NASDAQ: HALO  ) , a biopharmaceutical company that develops human enzymes that alter human tissues and make for more effective drug delivery, jumped as much as 25% after reporting its first-quarter results and providing an update on experimental pancreatic cancer drug PEGPH20 in study 202.

So what: The big share-price-driving news was the announcement from CEO Helen Torley that following its temporary halt of PEGPH20 in early April due to thromboembolic event concerns, the company supplied the data monitoring committee with additional requested information, and has been informed that "they [DMC] now support continued enrollment of patients and dosing of PEGPH20 in the trial with the proposed study modifications."

For the quarter, Halozyme produced $12 million in revenue, up slightly from the $11.8 million reported in the prior year, while its loss widened to $26.5 million, or $0.22 per share, from $19.3 million, or $0.17 per share in Q1 2013. As Halozyme noted, larger investments in its clinical pipeline results in its wider loss. By comparison, Wall Street was expecting a narrower loss of just $0.14 per share.

Now what: As with most predominantly clinical-stage companies, investors are more than willing to overlook a wider loss if it's to advance or expand a clinical pipeline. As for PEGPH20, its clinical hold should, in my opinion, never have resulted in the cataclysmic tumble that Halozyme shareholders endured. It's simply enrolling in a phase 2a study, and should hardly be a blip in terms of overall valuation for Halozyme, so it's good to see at least part of the company's value returning from its drop last month. With MabThera SC, which utilizes Halozyme's subcutaneous delivery technology, now approved in Europe, and Hylenex meeting the mark in the CONSISTENT-1 trial, I'd suggest that there could be some decent upside to Halozyme's shares here, and would encourage more risk-willing and biotech-savvy investors to take a deeper dive.

Halozyme shares may have soared today, but even it could struggle to keep pace with this top stock over the long run
Give me five minutes, and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer handpicks one stock with outstanding potential. But it's not just any run-of-the-mill company; it’s a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year, his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252%, and 1,303% during the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2955585, ~/Articles/ArticleHandler.aspx, 8/30/2014 12:11:55 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement